2026-06-14T03:54:04Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/198722025-05-07T08:52:23Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16967

00925njm 22002777a 4500 dc Mazagatos, Clara author Mendioroz, Jacobo author Rumayor-Zarzuelo, Mercedes Belén author Gallardo García, Virtudes author Álvarez Río, Virginia author Cebollada Gracia, Ana Delia author Batalla Rebollo, Noa author Barranco Boada, María Isabel author Pérez-Martínez, Olaia author Lameiras Azevedo, Ana Sofía author López González-Coviella, Nieves author Castrillejo, Daniel author Fernández Ibáñez, Ana author Giménez Duran, Jaume author Ramírez Córcoles, Cristina author Ramos Marín, Violeta author Larrauri, Amparo author Monge Corella, Susana author SARI Sentinel Surveillance RSV Study Group author 2024-05 Background: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards. Methods: Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23. Results: We estimated 9364-9875 RSV hospitalisations less than expected, corresponding to a 74%-75% reduction. Influenza Other Respir Viruses. 2024 May;18(5):e13294. 10.1111/irv.13294 1750-2659 Influenza and other respiratory viruses 38716791 http://hdl.handle.net/20.500.12105/19872 SARI Burden Impact Respiratory infections Respiratory syncitial virus Surveillance Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain